More than 750 FDA-approved drugs carry a known risk of drug-induced liver injury (DILI), yet many of these toxicities only come to light late in development or even after approval. To address this challenge, researchers are turning to in vitro 3D liver models that go beyond basic toxicity screening to deliver physiologically relevant data that can better predict DILI severity and improve early safety decision-making.
Download this application note to learn how a human liver-on-a-chip system enables efficient, accurate DILI risk prediction across various drug classes, from small molecules to antisense oligonucleotides.
